Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/056758external-prioritypatent/WO2009147149A1/en
Application filed by Ucb Pharma SafiledCriticalUcb Pharma Sa
Publication of TN2010000565A1publicationCriticalpatent/TN2010000565A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The present invention relates to compounds of formula (I) comprising a cyclobutoxy group, processes for preparing them, pharmaceutical compositions comprising said compounds and their use as pharmaceuticals, useful for the treatment and prevention of diseases or pathological conditions of the central nervous system including mild-cognitive impairments, Alzheimer's disease, learning and; memory disorders, cognitive disorders, attention deficit disorder, attention-deficit hyperactivity disorder, Parkinson's disease, schizophrenia, dementia, depression, epilepsy, seizures, convulsions, sleep/wake and arousal/vigilance disorders such as hypersomnia and narcolepsy, pain and/or obesity.
TNP2010000565A2009-06-022010-12-03Compounds comprising a cyclobutoxy group
TN2010000565A1
(en)
Compounds derived from 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta [a] naphthalenes, phosphodiestearase 2 and / or 10 inhibitors; pharmaceutical composition; and its use for prevention or treatment of diseases of the nervous system, such as cognitive deficiency, dementia, anxiety disorders, enf. from Alzheimer, enf. from parkinson, others
Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto